Endothelial cell dysfunction (ECD) is a common feature of chronic renal failure (CRF). Defective nitric oxide (NO) generation due to decreased endothelial NO synthase (eNOS) activity is a crucial parameter characterizing ECD. L-arginine is the sole precursor for NO biosynthesis. Among several transporters that mediate L-arginine uptake, cationic amino-acid transporter-1 (CAT-1) acts as the specific arginine transporter for eNOS. Our hypothesis implies that CAT-1 is a major determinant of eNOS activity in CRF. We studied glomerular and aortic arginine uptake, CAT-1, and CAT-2 messenger ribonucleic acid (mRNA) expression, and CAT-1 protein in: (a) rats 6 weeks following 5/6 nephrectomy (CRF), (b) sham-operated animals, and (c) rats with CRF treated orally with either atorvastatin or arginine in drinking water (modalities which have been shown to enhance eNOS activity and improve endothelial function). Both glomerular and aortic arginine transport were significantly decreased in CRF. Treatment with either arginine or atorvastatin abolished the decrease in arginine uptake in CRF rats. Using reverse transcriptase-polymerase chain reaction and Northern blotting, we found a significant increase in glomerular and aortic CAT-1 mRNA expression in CRF. Western blotting revealed that CAT-1 protein was decreased in CRF, but remained intact following arginine and atorvastatin administration. Renal and systemic arginine uptake is attenuated in CRF, through modulation of CAT-1 protein. These findings provide a possible novel mechanism to eNOS inactivation and endothelial dysfunction in uremia.
Endothelial cell dysfunction (ECD) is a common precursor and denominator of patients with chronic renal failure (CRF). This syndrome is currently interpreted as encompassing disturbances in several functions: the barrier function of vascular endothelium, its impaired antithrombogenic properties, blunted angiogenic capacity, inappropriate regulation of vascular smooth muscle tonicity, proliferative capacity, and migratory properties. 1 Accumulated evidence suggests that many of these abnormalities are linked to the capacity of the constitutive, Ca 2 þ /calmodulin-sensitive nitric oxide (NO) synthase (NOS) to generate adequate quantities of NO. 2 Indeed, reduction in NO generation has been reported in both experimental CRF and peritoneal, and hemodialysis patients. [3] [4] [5] [6] Abnormal function of the endothelial NOS (eNOS) system that results in ECD includes: decreased eNOS expression, alteration of NO signaling, destruction of NO by reactive oxygen species, and impaired availability of cofactors. 7 Our interest in this area is focused on the role of intracellular arginine availability in governing eNOS activity, thus affecting endothelial function. In vitro studies performed by Baylis et al. 8, 9 suggest that arginine uptake is decreased in renal failure. Moreover, they have shown that serum of uremic patients has the capacity to inhibit arginine uptake by cultured endothelial cells, an effect attributed to urea uptake by endothelial cells via urea transporter type B.
Among several transport systems that mediate L-arginine uptake (y þ , b 0, þ , B 0, þ , and y þ L), system y þ is widely expressed and considered to be a major arginine transporter in most tissues and cells. Encoded by cationic amino-acid transporters (CAT)-1, CAT-2, and CAT-3, system y þ is characterized by high affinity for cationic amino acids, sodium independence, and stimulation of transport by substrate on the opposite (trans) side of the membrane. 10, 11 Accumulated evidence from our laboratory and others suggest that each transporter has affinity to a specific NOS isoform. We have previously shown that arginine uptake by tubules or glomeruli harvested from rats subjected to ischemia and reperfusion or to sepsis, two experimental models characterized by activation of the inducible NOS, exhibit augmented arginine uptake, associated with upregulation of CAT-2. 12, 13 In contrast, we have also suggested that increased arginine uptake through upregulation of CAT-1 may contribute to the pathogenesis of diabetic hyperfiltration, via activation of eNOS. 14 Schafer et al. 15 have shown that suppression of the endothelium-mediated microvascular vasodilation by dexamethasone involves downregulation of eNOS and CAT-1. Moreover, CAT-1 and eNOS were found to be colocalized in a caveolar complex; 16 therefore, this complex has been suggested to serve as a mechanism for channeling of newly acquired extracellular arginine to eNOS, for NO synthesis. In the aggregate, it is believed that arginine is delivered to eNOS predominantly by CAT-1.
Experiments described herein were designed to determine whether glomerular and aortic arginine uptake are altered in an in vivo model of CRF and to elucidate whether these changes are related to the specific eNOS arginine transporter CAT-1 mRNA expression and protein abundance in these tissues. In addition, we studied the beneficial effects of arginine and statins, two modalities previously shown to improve endothelial function, on the above parameters, aiming to link our findings to ECD in CRF.
RESULTS

Effects of atorvastatin and L-arginine on creatinine clearance
To consolidate previous observations and validate the therapeutic efficiency of arginine and atorvastatin in CRF, creatinine clearance (CCr) was measured in all experimental groups ( Figure 1 ). CRF resulted in a significant decrease in CCr (0.2370.04 vs 0.5570.05 ml/min/100 g body weight (BW), Po0.01). Administration of L-arginine or atorvastatin significantly attenuated the decrease in CCr in CRF animals (0.4770.09 and 0.4270.08 ml/min/100 g BW, respectively).
Aortic and glomerular arginine transport
Initially, we wished to explore the possibility that CRF affects the characteristics of y þ system, the predominant arginine uptake system. Figure 2a and b demonstrates that, in aortic rings and glomeruli harvested from animals subjected to 5/6 nephrectomy, arginine transport system remained sodium independent. Excess concentration of lysine strongly inhibited L-arginine uptake, while the neutral amino acid methionine was found to be a poor inhibitor. In addition, we characterized the kinetics of L-arginine transport in both tissues by measuring the saturable uptake of L-arginine (0-1 mM). The plots of L-arginine uptake as a function of extracellular L-arginine concentration are shown in Figure 3a and b. A high-affinity transporter was found to be present with a K m of 120 and 125 mM in aortic rings and glomeruli, respectively. These data establish that, in glomeruli and aortic rings from rats with CRF, system y þ remains the predominant arginine transport system, with kinetic properties that resemble those of CAT-1 and CAT-2.
The next set of experiments was designed to explore a possible effect of CRF on y þ system and the impact of agents that have been shown to improve endothelial function via modulation of the NO system, namely arginine and statins. We have chosen to perform these experiments in both aortic and renal tissues in order to explore differences between renal and systemic circulation. When compared to normal rats, CRF induced a significant (B50%) decrease in both aortic and glomerular arginine uptake. Treatment of CRF rats with either arginine or atorvastatin completely abolished this effect (Figure 4a and b) . To determine whether the observed CRF-induced changes in arginine uptake are associated with similar directional changes in mRNA levels for CAT family of transporters, total aortic and glomerular RNA was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) to amplify portions of CAT-1 and CAT-2. We identified complementary deoxyribonucleic acid (cDNA) encoding both CAT-1 and CAT-2 in the glomeruli and aortic rings harvested from control rats. Surprisingly, CRF significantly augmented the expression of CAT-1 mRNA in both aortic rings and glomeruli. Treating CRF rats with either arginine or atorvastatin abolished the increase in CAT-1 mRNA in the aortic strips (Figure 5a and b), while no significant effect was observed in glomeruli ( Figure 6a and b). CAT-2 remained unchanged in CRF rats (data not shown).
To further confirm this observation, Northern blotting was performed. CRF rats exhibited a significant increase in aortic and glomerular steady-state CAT-1 mRNA levels, which were not affected by cotreatment with either arginine or atorvastatin (Figure 7a-d ).
Glomerular and aortic CAT-1 protein in CRF
To further explore a possible role for CAT-1 in arginine traffic in CRF, we examined CAT-1 protein levels. CAT-1 protein was identified as B90 kDa, in both glomerular and aortic tissues. Studies on CAT-1 protein have been hampered by difficulties in generating anti CAT-1 antibodies and some variability in the band's size, probably reflecting different degrees of glycosylation of the protein, as shown previously for other transporters. 17 To verify our findings, we used anti CAT-1 antibodies directed against two different epitopes. Both antibodies yielded a similar, B90 kDa band. The specificity of the antibody was demonstrated by incubating our membranes with anti-CAT-1 antibody in the presence of the antigenic peptide, which indeed blocked the appearance of the 90-kDa protein bands. We found that CAT-1 abundance was significantly decreased in tissues harvested from CRF rats. Treatment with either atorvastatin or arginine prevented this phenomenon (Figure 8a-d) . Western blotting to CAT-2 protein was not performed due to failure to synthesize anti-CAT-2 antibodies. 
DISCUSSION
The present study demonstrates that both glomerular and aortic arginine uptake are attenuated in an in vivo model of CRF. Molecular analysis reveals that while CAT-2 mRNA levels are not altered, those of CAT-1 are paradoxically increased. In contrast, CAT-1 protein abundance is decreased. Both arginine and atorvastatin prevented the decrease in arginine uptake velocities and CAT-1 protein level. These data suggest a novel mechanism for the decrease in eNOS activity and thus for endothelial dysfunction, which are characteristic of CRF. In addition, they provide an explanation for amelioration of endothelial function mediated by arginine or 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors in CRF.
Our data are consistent with those of a previous study by Baylis et al., 8, 9 who reported a decrease in arginine uptake by cultured endothelial cells exposed to uremic serum. This effect was reversed by blocking urea flux, suggesting that urea inhibits arginine transport. Comparison between the latter study and ours reveals that the magnitude of the uremic effect was more pronounced in our experimental model. A different methodology could serve as an explanation to the above observation. Substances other than urea, which account for the uremic milieu, may become apparent in vivo but not in vitro. Indeed, the same group has reported that uremic levels of blood urea nitrogen do not alter NO metabolism in normal rats. 18 One plausible candidate is the endogenous arginine analog asymmetric dimethyl arginine (ADMA). High extracellular levels of ADMA have been reported in CRF and were shown to attenuate NO generation, yet, did not affect arginine uptake in vitro. 8 Of note, in vivo intracellular levels of ADMA in uremic conditions are unknown, and may be higher than plasma levels. Therefore, impaired availability of L-arginine induced by ADMA may impact cellular NO production only when studied in vivo.
We have tried to elucidate a molecular mechanism to explain our findings. The fact that the changes observed in arginine uptake were associated with CAT-1 (but not with CAT-2) expression strengthens the hypothesis that these events are mediated by eNOS activity: CAT-1 colocalizes with eNOS in the endothelial cell caveola, thus acting as a specific supplier of arginine for eNOS. 16 This conclusion bears a limitation as exclusivity of CAT-1 was not fully established since we were unable to follow CAT-2 protein. Our data clearly establish that, in CRF, CAT-1 expression is primarily regulated at the post-transcriptional level. The question raised from these studies is why CAT-1 mRNA level increases in CRF without being translated into more CAT-1 protein.
One can speculate that the increase in CAT-1 mRNA transcription, or stability, compensates for inefficient translation, yet fails to sustain adequate CAT-1 protein level. A similar finding for CAT-1 has been reported in amino-aciddepleted C6 glia and NRK (normal rat kidney) kidney cells, when compared with amino-acid-fed cells. 19 Future studies will show if factors besides urea are involved in downregulation of CAT-1 protein in CRF.
To further define the relationship between CAT-1 activity and endothelial function in uremia, we examined the effect of atorvastatin and arginine on CAT-1 in CRF. It is well established that the beneficial effects of statins in CRF are far beyond lipid-lowering properties. They have been shown to improve vessel stiffness in CRF and inhibit inflammation in dialysis patients, implying that these agents improve endothelial function. 20 Hence, the beneficial effect is complex and not completely understood. Inhibition of HMG-CoA reductase results in depleted downstream products of mevalonate, which are critical elements for post-translational modification of ubiquitous signaling proteins such as G proteins, guanine 5 0 -triphosphate-binding protein Ras, and Rho family members. These effects have been shown to result in augmented eNOS expression. 21, 22 Our observation, that atorvastatin has a beneficial effect on CAT-1, implies the existence of a new regulatory mechanism by which statins modify eNOS activity, thus ameliorating endothelial function in CRF.
Given the fact that intracellular levels of L-arginine far exceed the K m of NOS enzyme, it appears unlikely that the administration of substrate affects cellular NO production. Surprisingly, numerous studies unequivocally demonstrated, both in animals and humans, beneficial effects for arginine administration on vascular response, including conditions such as hypercholesterolemia, hypertension, and diabetes. [23] [24] [25] Furthermore, even oral feeding of arginine, which only doubles plasma arginine levels, was found to have beneficial effects on atherosclerosis development in cholesterol-fed rabbits and in hypertensive rats. 25, 26 Reyes et al. proteinuria, and higher GFR. This phenomenon, in which arginine supplementation stimulates NO synthesis despite saturating intracellular concentrations, can be explained by our results. We found that oral arginine administration to CRF rats prevented the decrease in arginine uptake and preserved CAT-1 protein abundance. If arginine is selectively introduced to eNOS by CAT-1, then the protective effect of arginine on CAT-1 can serve as a plausible explanation for the findings described by Reyes et al.: Thus, it is not solely the increase in extracellular arginine concentration but rather the preservation of CAT-1 ability 'to feed' eNOS with its substrate, which may constitute the beneficial effect of arginine on eNOS activity in CRF.
Being limited in our capacity to attenuate the progression of chronic kidney disease, the present study suggests that future efforts should be directed to sustain CAT-1 expression and activity in order to improve endothelial function in CRF. Our data support the therapeutic effects of statins and arginine in patients with CRF.
MATERIALS AND METHODS Materials
All standard reagents were obtained from Sigma Chemical Co., St. Louis, MO, USA, unless indicated otherwise. [H 3 ]L-arginine was supplied by Perkin-Elmer, Life and Analytical Sciences, Boston, MA, USA.
Animals and surgical preparation
All animal experiments described in this study were conducted in accord with the protocol approved by the institutional committee on ethics in animal experiments. Studies were performed using male Wistar rats weighing 200-250 g. Subsequently, rats were segregated into four groups, respectively: Group 1: control, sham-operated rats. Group 2: CRF, rats underwent a two-stage 5/6 nephrectomy (interval of one week). Following the operation, animals were allowed to recover and have free access to a standard rat chow and tap water. Experiments were performed 6 weeks following the second surgery. Group 3: CRF þ L-arginine: CRF rats were given L-arginine 1% in drinking water, starting from day 1. Group 4: CRF þ statin: CRF animals were treated with atorvastatin, 10 mg/kg BW/day in drinking water starting from day 1.
CCr was measured, prior to killing, in all experimental groups as described previously. 28 L-arginine uptake by aortic rings Uptake of radiolabeled L-arginine in the rat aorta was measured according to previously described methods with modification. Immediately after the rat was killed, the aorta was carefully excised from the left renal artery to the aortic valve ring and placed in icecold HEPES buffer. The vessels were dissected free from adherent connective tissue and cut into rings (length 3-4 mm). Each segment was cut longitudinally into halves. To determine arginine transport, aortic segments of each experimental group were incubated and shaken for 10 min in HEPES buffer at pH 7.4, 371C. L-[
3 H]arginine and L-arginine, in a final concentration of 1 mM, were added to a total volume of 2 ml for additional 1 min. The duration of 1 min was chosen since it was within the linear portion of uptake curves (data not shown). Transport was terminated by rapidly washing the aortic rings with ice-cold phosphate-buffered saline (PBS) buffer (four times, 3 ml/tube). The rings were then dried and solubilized in 1 ml of 0.5% sodium dodecyl sulfate (SDS) in 0.5 N NaOH. In all, 700 ml of the lysate was used to monitor radioactivity, by liquid scintillation spectrometry (Betamatic, Kontron, St. Louis, MO, USA). The remaining 300 ml was used for protein content determination by the Lowry method (Lowry assay Kit, Sigma Co.) To correct for nonspecific uptake or cell membrane binding, additional studies were performed in which aortic segments were incubated with 10 mM unlabeled arginine in HEPES buffer, and the associated radioactivity was subtracted from each data point. Results are expressed as mean7s.e. of at least five different experiments.
L-arginine uptake by freshly harvested glomeruli Isolation of glomeruli and arginine uptake was performed essentially as described previously. [12] [13] [14] In brief, glomerular suspensions from the various experimental groups were incubated and shaken for 10 min in HEPES buffer at pH 7.4, 371C. L- [H 3 ]arginine and L-arginine, in a final concentration of 1 mM, were added to a total volume of 1 ml for additional 1 min. Transport activity was terminated by rapidly washing the cells with ice-cold PBS buffer (four times, 2 ml/tube). The glomeruli were then dried and solubilized in 1 ml of 0.5% SDS in 0.5 N NaOH. A volume of 700 ml of the lysate was used to monitor radioactivity and the remaining 300 ml was used for protein content, as described in the previous section. Results are expressed as mean7s.e. of at least five different experiments.
Analysis of mRNA levels for CAT-1 and CAT-2 by RT-PCR Total cellular RNA was extracted from glomeruli or aortic rings following the method described by Chomeczynski and Sacchi. 29 Reverse transcription was carried out for 1.5 h at 421C, and PCR in 10 Â buffer for a total of 35 cycles, each of 941C for 1 min, 601C for 1 min, 721C for 2 min, and 7 min (final cycle) (Promega, Madison, WI). The first pair of primers was designed to bind to a portion of the rat CAT-1 gene: forward 21-mer, 5
0 -GCCATCGTCAT CTCCTTCCTG-3 0 , and reverse 21-mer, 5 0 -CCCTCCCTCACCG TATTTCAC-3 0 expression. A second pair of primers, which hybridize to a sequence, common to both CAT-2 and CAT-2A were: forward 24-mer, 5 0 -AACGTGCTTTTATGCCTTTGT-3 0 , and reverse 23-mer, 5 0 -GGTGACCTGGGACTCGCTCTT-3 0 . 30 To exclude the possibility of contamination by genomic DNA amplification, and to assess the adequacy of cDNA, experiments were carried out in the absence of reverse transcriptase. Amplification of glyceraldehyde 3 phosphate dehydrogenase (GAPDH) was performed, respectively. PCR products were electrophoresed on a 1.6% agarose gel and visualized by UV-induced fluorescence. All PCR reactions resulted in the amplification of a single product of the predicted size for CAT-1, CAT-2/2A, and GAPDH.
Northern blot analysis
Prehybridization for CAT-1 mRNA level was determined by northern hybridization. In all, 20 mg of total RNA was denatured and fractionated by size on 1.3% formaldehyde-agarose gel. RNA was transferred overnight, by capillary action, to a nylon membrane (Hybond-N, Amersham International, Buckinghamshire, UK), and crosslinked by short-wave ultraviolet illumination. Purified end products of CAT-1 and GAPDH cDNA (High pure TM PCR product purification Kit) (Boehringer Mannheim, Germany) were used directly for radiolabeling with [P 32 ]deoxycytidine triphosphate by a random primer labeling method (Random primers DNA Labeling System Kit) (Gibco BRL, Gaithersburg, MD, USA). After 1 h at 501C, membranes were hybridized overnight at 501C with the 32 P-labeled cDNA. Membranes were sequentially washed twice in 1 Â standard sodium citrate (SSC), 0.1% SDS for 15 min, at room temperature, once in 1 Â SSC, 0.1% SDS for 15 min at 501C, followed by 0.5 Â SSC, 0.1% SDS at 551C for 30 min, and then washed at high stringency in 0.1 Â SSC, 0.1% SDS at 571C for 15 min. Autoradiography was carried out with Kodak XAR film (Kodak, Rochester, NY, USA) for 24-48 h at À801C. Relative mRNA abundance was quantified by measuring the density of the exposed film with a densitometer (BIS 202D) (Fuji, Tokyo, Japan). CAT-1 mRNA level was normalized to GAPDH mRNA and expressed in arbitrary units as the ratio of CAT-1 to GAPDH expression in four different experiments.
CAT-1 protein quantification by Western blotting CAT-1 protein expression in aortas and glomeruli was determined by Western blot analysis. Briefly, excised aortas and glomeruli were separately placed in ice-cold PBS lysis buffer (pH 7.4), containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 4.5 mM leupeptin, and 5 mM aprotinin) (ICN Biomedicals Inc., Irvine, CA, USA), 0.01% Triton X-100, and 0.1% SDS, mechanically homogenized, and left on ice for 45 min. Homogenates were subsequently centrifuged (13 000 r.p.m. for 10 min, at 41C). Cell lysates were stored in aliquots in À701C. A membrane fraction was obtained by adding to the pellet an equal volume of lysis buffer supplemented by Tween-20 (0.25%) to solubilize. The protein content of each sample was determined by the method of Lowry. Equal amounts of protein (30 mg) were prepared in sample buffer (2% SDS, 0.01% bromophenol blue, 25% glycerol, 0.0625 M Tris HCL, pH 6.8, 5% mercaptoethanol) and analyzed on a 7.5% SDS-polyacrylamide electrophoresis gel. The gel was transferred onto Hybond ECL nitrocellulose membranes (Amersham Corp.), and blocked in PBS with bovine serum albumin (PBS-T) containing 5% nonfat dried milk at room temperature. Membranes were then incubated with polyclonal rabbit anti-rat CAT-1 antibodies, 1:500 and 1:200 for peptide-1 and peptide-2, respectively (synthesized by Dr O Leitner, Weizmann Institute, Rehovot, Israel), for 1 h at room temperature, washed, and incubated with secondary horseradish peroxidaseconjugated goat anti-rabbit antibody (1:10 000) in PBS-T for 1 h. Membranes were washed three times, for 5 min each, in PBS-T. Membranes were then stripped and reprobed with b-actin. CAT-1 was detected by enhanced chemiluminescence (Kodak X-OMAT AR film) and quantified by densitometry.
Statistical analysis
Means7s.e. one-way analysis of variance for comparison between groups and Student's t-test between two groups were computed and used to assess the statistical significance. P-values o0.05 were considered to be statistically significant.
